Objective: The aim of the present study was to develop and evaluate nanostructured lipid
carrier based topical hydrogel of mometasone furoate for the treatment of psoriasis.
Method: Drug loaded NLCs were successfully developed by microemulsion technique. Pseudo ternary
phase diagrams were constructed using different combinations of surfactant and co-surfactants to
study the microemulsion existence range. Different compositions were selected from the phase diagram
showing maximum microemulsion region and were converted into NLCs by dilution in water
(1:20). The optimized formulation was characterised for droplet size, zeta potential, entrapment efficiency
and morphology was studied using Transmission Electron Microscopy. Ex vivo permeation
studies were carried out using Wistar rat skin. The potential of this formulation in treating psoriatic
inflammation was studied using imiquimod induced skin inflammation animal model.
Results: The optimized formulation (F4) has droplet size of 163.2±0.522 nm, zeta potential -
0.086±0.099 mV and entrapment efficiency of 60.0±0.187%. Transmission electron microscopy confirmed
spherical shape of nanostructured lipid carrier. Carbopol 940 was used to convert NLC dispersion
into NLC based hydrogel to improve its viscosity for topical administration. Drug permeation
studies showed prolonged drug release from the NLC based gel as compared to marketed formulation
following Higuchi release kinetics. The skin deposition of MF loaded NLC based hydrogel was found
to 2.5 fold higher than marketed formulation with primary skin irritation index of 0.20. In vivo studies
showed complete clearance of parakeratosis by treatment with the prepared NLC formulation. Accelerated
stability studies signify high robustness scale of optimized formulation under one month storage
Conclusion: The prepared NLC based formulation has proved to be a promising carrier system for the
treatment of psoriasis.